Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | LTA4H | P09960 | 4/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | TACR3 | P29371 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3418650 | 0.89 | KDM1A (0.44) | ALDH1A1RAB9ANPC1SMN1; SMN2LMNA | |
| SCHEMBL6042110 | 0.79 | REN (0.49) | — | |
| SCHEMBL3081977 | 0.78 | PPARG (0.39) | ALDH1A1POLBRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL2852728 | 0.77 | DRD4 (0.39) | ALDH1A1 | |
| SCHEMBL2852733 | 0.77 | DRD4 (0.39) | ALDH1A1 | |
| SCHEMBL3072160 | 0.77 | YAP1 (0.49) | — | |
| SCHEMBL3079026 | 0.75 | REN (0.48) | — | |
| SCHEMBL6043843 | 0.75 | SLC6A2 (0.39) | POLBSMN1; SMN2 | |
| SCHEMBL6043974 | 0.74 | SMN1; SMN2 (0.43) | ALDH1A1RAB9ANPC1SMN1; SMN2LMNA | |
| SCHEMBL6043979 | 0.74 | SMN1; SMN2 (0.43) | ALDH1A1RAB9ANPC1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790715-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-07 | — | — | US | disclosed |
| US-20070010511-A1 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010511-A1 | Organic compounds | REN, ACE, ACE2 | ALDH1A1 142/4885POLB 1031/4885RAB9A 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.